← Back to Directory

Bempedoic Acid

Nexletol, Nilemdo

Visual ViewRaw DataInteraction Data

Meta Information

ID:bempedoic-acid
Name:Bempedoic Acid
Schema Version:1.5

Title

Bempedoic Acid

Alternate Names

  • Nexletol
  • Nilemdo

Intervention Type

therapeutic_agent

Expected Cost Mean

Low Cost:
400
High Cost:
550
Cost Type:
monthly
Description:
Brand-name prescription drug; cost varies significantly with insurance coverage.

Summary

Bempedoic acid lowers LDL cholesterol by inhibiting ATP-citrate lyase (ACL), an enzyme upstream of the statin target HMG-CoA reductase. It is a prodrug activated primarily in the liver, which may reduce the muscle-related side effects associated with statins. Its primary healthspan relevance is the significant reduction of atherosclerotic cardiovascular disease (ASCVD) risk, a leading cause of age-related mortality and morbidity.

Purpose

Lowers LDL cholesterol to reduce long-term cardiovascular disease risk.

Card Summary

A non-statin oral drug that lowers LDL cholesterol, primarily for statin-intolerant individuals.

Drug Class

atp-citrate-lyase-inhibitors

Drugs In Class

Empty Array

Impact

Score:
6.5
Justification:
Highly effective at lowering LDL-C, a key driver of age-related cardiovascular disease.

Evidence

Grade:
A
Score:
9
Justification:
Multiple large-scale human RCTs confirm LDL reduction and improved cardiovascular outcomes.

Safety

Score:
4.8
Justification:
Generally well-tolerated but carries risks of hyperuricemia, gout, and rare tendon rupture.

Flags

  • Requires a prescription and medical supervision.
  • May increase uric acid levels, potentially triggering gout in susceptible individuals.
  • Carries a small but increased risk of tendon rupture.
  • Increases blood levels of simvastatin and pravastatin, requiring dose adjustments.

Verdict

A valuable statin alternative for lowering LDL and cardiovascular risk.

Created

2026-04-23T22:45:11.531259Z

Model

Gemini 3.1 Pro (High)

Delivery

Route:
oral
Scope:
  • systemic

Indication

Focus:
healthspan
Description:
Bempedoic acid lowers LDL cholesterol by inhibiting ATP-citrate lyase (ACL), an enzyme upstream of the statin target HMG-CoA reductase. It is a prodrug activated primarily in the liver, which may redu...

Typical Protocol

  • A standard dose is 180 mg taken orally once daily, with or without food.